View More Recent Stories

Nov 16, 2021 08:00AM CNS Pharmaceuticals to Present at the Virtual Investor Roundtable Event
Nov 4, 2021 02:30PM JTC Team to Host Virtual Investor Roundtable Event on November 16th, 17th, and 18th
Oct 11, 2021 08:00AM CNS Pharmaceuticals Inc. Featured in Syndicated Broadcast Covering Dosing of First Patients in Its Berubicin Clinical Development Program for Glioblastoma Multiforme
Sep 30, 2021 08:05AM CNS Pharmaceuticals Doses First Group of Patients with Berubicin, an FDA-Designated Fast Track Drug Candidate, in the Potentially Pivotal Study for the Treatment of Glioblastoma Multiforme (GBM)
Aug 13, 2021 08:05AM CNS Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides Business Outlook
Jul 1, 2021 09:05AM CNS Pharmaceuticals Continues to Execute on Corporate, Clinical and Regulatory Strategies to Drive Berubicin Towards Commercialization for the Treatment of GBM
Jun 29, 2021 08:36AM CNS Pharmaceuticals (CNSP) Announces FDA Grants Fast Track Designation to Berubicin for the Treatment of Recurrent Glioblastoma Multiforme
Jun 29, 2021 08:35AM FDA Grants Fast Track Designation to CNS Pharmaceuticals for Berubicin for the Treatment of Recurrent Glioblastoma Multiforme
Jun 17, 2021 09:05AM CNS Pharmaceuticals Announces Inclusion in the Russell 2000® Index
View More Recent Stories